Compare Stocks: KMDA, KARD, LKFT, and DMRA

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$29.00 -5.2%	$29.22	$2.45 ▼ $38.33	$1.79B	1.47	322,628 shs	371,724 shs
KARD Kardigan	$20.02 -3.8%	$21.88	$16.25 ▼ $27.00	$1.87B	N/A	235,121 shs	196,556 shs
KMDA Kamada	$8.29 +0.4%	$7.39	$6.50 ▼ $9.35	$476.72M	0.86	164,224 shs	55,081 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$28.88 -1.9%	$28.76	$25.68 ▼ $37.78	$1.90B	0.27	277,556 shs	143,741 shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	-5.91%	-0.72%	+16.56%	+763.10%
KARD Kardigan	0.00%	-4.76%	-2.20%	+2,001,999,900.00%	+2,001,999,900.00%
KMDA Kamada	0.00%	+0.61%	+16.76%	+6.15%	+16.27%
LKFT Lakefront Biotherapeutics American Depositary Shares	0.00%	+0.28%	+4.49%	+1.87%	-12.25%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DMRA Damora Therapeutics, Inc. Common Stock	$29.00 -5.2%	$29.22	$2.45 ▼ $38.33	$1.79B	1.47	322,628 shs	371,724 shs
KARD Kardigan	$20.02 -3.8%	$21.88	$16.25 ▼ $27.00	$1.87B	N/A	235,121 shs	196,556 shs
KMDA Kamada	$8.29 +0.4%	$7.39	$6.50 ▼ $9.35	$476.72M	0.86	164,224 shs	55,081 shs
LKFT Lakefront Biotherapeutics American Depositary Shares	$28.88 -1.9%	$28.76	$25.68 ▼ $37.78	$1.90B	0.27	277,556 shs	143,741 shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DMRA Damora Therapeutics, Inc. Common Stock	0.00%	-5.91%	-0.72%	+16.56%	+763.10%
KARD Kardigan	0.00%	-4.76%	-2.20%	+2,001,999,900.00%	+2,001,999,900.00%
KMDA Kamada	0.00%	+0.61%	+16.76%	+6.15%	+16.27%
LKFT Lakefront Biotherapeutics American Depositary Shares	0.00%	+0.28%	+4.49%	+1.87%	-12.25%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DMRA Damora Therapeutics, Inc. Common Stock	3.00	Buy	$44.00	51.72% Upside
KARD Kardigan	2.80	Moderate Buy	$42.25	111.04% Upside
KMDA Kamada	3.00	Buy	$13.00	56.82% Upside
LKFT Lakefront Biotherapeutics American Depositary Shares	2.33	Hold	$30.67	6.19% Upside

Current Analyst Ratings Breakdown

Latest KMDA, KARD, LKFT, and DMRA Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/27/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold (C-) ➝ Hold (C)
8/25/2026	KARD Kardigan	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$51.00 ➝ $46.00
8/24/2026	DMRA Damora Therapeutics, Inc. Common Stock	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$30.00 ➝ $26.00
8/11/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$28.00 ➝ $26.00
8/4/2026	LKFT Lakefront Biotherapeutics American Depositary Shares	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/30/2026	DMRA Damora Therapeutics, Inc. Common Stock	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$35.00 ➝ $40.00
7/27/2026	DMRA Damora Therapeutics, Inc. Common Stock	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$50.00
7/21/2026	KMDA Kamada	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
7/21/2026	KMDA Kamada	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$15.00

(Data available from 8/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	$6.25 per share	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$180.46M	2.64	$0.61 per share	13.58	$4.69 per share	1.77
LKFT Lakefront Biotherapeutics American Depositary Shares	$990.57M	1.92	$0.73 per share	39.78	$57.58 per share	0.50

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DMRA Damora Therapeutics, Inc. Common Stock	-$209.84M	-$3.37	N/A	N/A	N/A	N/A	-176.39%	-77.86%	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$20.20M	$0.38	21.82	13.82	0.68	11.60%	8.37%	5.85%	11/9/2026 (Estimated)
LKFT Lakefront Biotherapeutics American Depositary Shares	$363.05M	-$1.41	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest KMDA, KARD, LKFT, and DMRA Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	KMDA Kamada	$0.1125	$0.16	+$0.0475	$0.16	$50.84 million	$54.92 million
8/11/2026	Q2 2026	KARD Kardigan	N/A	-$4.61	N/A	-$4.61	N/A	N/A
8/10/2026	Q2 2026	DMRA Damora Therapeutics, Inc. Common Stock	-$0.4470	-$0.39	+$0.0570	-$0.39	N/A	N/A
8/10/2026	Q2 2026	LKFT Lakefront Biotherapeutics American Depositary Shares	-$0.9672	$0.04	+$1.0072	$0.04	$7.29 million	$15.47 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
DMRA Damora Therapeutics, Inc. Common Stock	N/A	N/A	N/A	N/A	N/A
KARD Kardigan	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	$0.13	1.57%	N/A	34.21%	N/A
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	N/A	N/A	N/A	N/A

Latest KMDA, KARD, LKFT, and DMRA Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
8/17/2026	KMDA Kamada	annual	$0.17	2.06%	8/27/2026	8/27/2026	9/17/2026

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DMRA Damora Therapeutics, Inc. Common Stock	N/A	19.73	19.73
KARD Kardigan	N/A	N/A	N/A
KMDA Kamada	N/A	4.06	2.29
LKFT Lakefront Biotherapeutics American Depositary Shares	N/A	32.84	32.72

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DMRA Damora Therapeutics, Inc. Common Stock	14.20%
KARD Kardigan	N/A
KMDA Kamada	20.38%
LKFT Lakefront Biotherapeutics American Depositary Shares	32.46%

Insider Ownership

Company	Insider Ownership
DMRA Damora Therapeutics, Inc. Common Stock	0.40%
KARD Kardigan	N/A
KMDA Kamada	36.10%
LKFT Lakefront Biotherapeutics American Depositary Shares	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DMRA Damora Therapeutics, Inc. Common Stock	40	61.74 million	61.49 million	No Data
KARD Kardigan	N/A	93.50 million	N/A	N/A
KMDA Kamada	360	57.51 million	36.75 million	Optionable
LKFT Lakefront Biotherapeutics American Depositary Shares	1,310	65.90 million	63.98 million	Optionable

KMDA, KARD, LKFT, and DMRA Headlines

Recent News About These Companies

Acquisition of Own Shares

August 25, 2026 | globenewswire.com

Lakefront Receives Transparency Notification from Bank of America

August 24, 2026 | globenewswire.com

U.S. FDA Grants Orphan Drug Designation to Gamgertamig for the Treatment of Pemphigus

August 24, 2026 | globenewswire.com

TD Cowen Initiates Coverage on Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT)

August 21, 2026 | marketbeat.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Pass Below 200 Day Moving Average - Here's Why

August 19, 2026 | americanbankingnews.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price Cross Below Two Hundred Day Moving Average - Time to Sell?

August 19, 2026 | marketbeat.com

Acquisition of Own Shares

August 18, 2026 | globenewswire.com

Acquisition of Own Shares

August 12, 2026 | globenewswire.com

Royal Bank Of Canada Has Lowered Expectations for Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Stock Price

August 11, 2026 | marketbeat.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Given Average Rating of "Hold" by Analysts

August 11, 2026 | marketbeat.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Posts Earnings Results, Beats Expectations By $1.01 EPS

August 10, 2026 | marketbeat.com

Lakefront Biotherapeutics American Depositary Shares (NASDAQ:LKFT) Sets New 52-Week Low - Here's What Happened

August 3, 2026 | marketbeat.com

Lakefront Biotherapeutics American Depositary Shares (LKFT) Expected to Post Quarterly Earnings on Monday

August 3, 2026 | marketbeat.com

Acquisition of Own Shares

July 28, 2026 | globenewswire.com

Acquisition of Own Shares

July 21, 2026 | globenewswire.com

Lakefront Biotherapeutics Earnings Estimates, EPS & Revenue | NASDAQ:LKFT

July 15, 2026 | benzinga.com

Acquisition of Own Shares

July 14, 2026 | globenewswire.com

Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi

July 13, 2026 | globenewswire.com

Morgan Stanley resumes Lakefront at equal weight after Ouro buyout

July 10, 2026 | msn.com

Acquisition of Own Shares

July 7, 2026 | globenewswire.com

Acquisition of Own Shares

June 30, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

KMDA, KARD, LKFT, and DMRA Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

$29.00 -1.60 (-5.23%)

As of 08/28/2026 04:00 PM Eastern

Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is headquartered in Copenhagen, Denmark.

Kardigan NASDAQ:KARD

$20.02 -0.78 (-3.75%)

As of 08/28/2026 04:00 PM Eastern

Kardigan Inc. is a clinical-stage precision therapeutics company developing medicines which target the root cause of specific cardiovascular diseases. Kardigan Inc. is based in South San Francisco, California.

Kamada NASDAQ:KMDA

$8.29 +0.03 (+0.36%)

As of 08/28/2026 04:00 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

$28.88 -0.56 (-1.90%)

As of 08/28/2026 04:00 PM Eastern

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc.; and AbbVie S.à r.l. Galapagos NV was incorporated in 1999 and is headquartered in Mechelen, Belgium.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest KMDA, KARD, LKFT, and DMRA Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest KMDA, KARD, LKFT, and DMRA Earnings

Compare Dividends

Latest KMDA, KARD, LKFT, and DMRA Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

KMDA, KARD, LKFT, and DMRA Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

KMDA, KARD, LKFT, and DMRA Company Descriptions

Damora Therapeutics, Inc. Common Stock NASDAQ:DMRA

Kardigan NASDAQ:KARD

Kamada NASDAQ:KMDA

Lakefront Biotherapeutics American Depositary Shares NASDAQ:LKFT

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools